Bank of America
SNDX icon

Bank of America’s Syndax Pharmaceuticals SNDX Stock Holding History

Bank of America’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-105,000
Closed -$2.02M – 8391
2024
Q3 		$2.02M Buy
+105,000
New +$2.17M ﹤0.01% 4555

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America's SNDX Position: Q1 2026 in Review

Bank of America reduced its Syndax Pharmaceuticals (SNDX) stake by 9.8% in Q1 2026, selling an estimated $10M and leaving 4,249,836 shares worth $99.3M. The position accounts for 0.01% of the portfolio, ranked #1119.

Bank of America first reported a position in SNDX in Q2 2016 and has held it in 40 quarters since. 247 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Bank of America held 4,249,836 shares of Syndax Pharmaceuticals worth $99.3M as of Q1 2026.
  • Bank of America sold 460,910 Syndax Pharmaceuticals shares in Q1 2026, an estimated $10M.
  • Syndax Pharmaceuticals made up 0.01% of Bank of America's portfolio in Q1 2026, its #1119 holding.
  • Bank of America first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 40 quarters since.
  • 247 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.